Skip to content
10-K

Annual Report

Sonoma Pharmaceuticals, Inc. SNOA

0001683168-26-004871

← back to feed
Filed
Jun 16, 2026 12:00 AM ET
Period of report
Jun 15, 2026

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2026 · Jun 15, 2026 4.79M sh
Shares Diluted FY 2026 · Mar 31, 2026 1.68M sh
Shares Diluted FY 2026 · Mar 31, 2025 1.24M sh
Capex FY 2026 · Mar 31, 2026 $192K
Capex FY 2026 · Mar 31, 2025 $80K
Operating Cash Flow FY 2026 · Mar 31, 2026 −$3.93M
Operating Cash Flow FY 2026 · Mar 31, 2025 −$88K
Short Term Debt FY 2026 · Mar 31, 2026 $222K
Short Term Debt FY 2026 · Mar 31, 2025 $220K
Cash And Equivalents FY 2026 · Mar 31, 2026 $2.4M
Cash And Equivalents FY 2026 · Mar 31, 2025 $5.37M
Stockholders Equity FY 2026 · Mar 31, 2026 $3.1M
Stockholders Equity FY 2026 · Mar 31, 2025 $4.41M
Stockholders Equity FY 2026 · Mar 31, 2024 $6.14M
Current Liabilities FY 2026 · Mar 31, 2026 $4.83M
Current Liabilities FY 2026 · Mar 31, 2025 $4.1M
Total Liabilities FY 2026 · Mar 31, 2026 $10.87M
Total Liabilities FY 2026 · Mar 31, 2025 $9.28M
Current Assets FY 2026 · Mar 31, 2026 $12.1M
Current Assets FY 2026 · Mar 31, 2025 $12.65M
Total Assets FY 2026 · Mar 31, 2026 $13.96M
Total Assets FY 2026 · Mar 31, 2025 $13.69M
Eps Diluted FY 2026 · Mar 31, 2026 −$1.89
Eps Diluted FY 2026 · Mar 31, 2025 −$2.79
Eps Basic FY 2026 · Mar 31, 2026 −$1.89
Eps Basic FY 2026 · Mar 31, 2025 −$2.79
Sga Expense FY 2026 · Mar 31, 2026 $7.61M
Sga Expense FY 2026 · Mar 31, 2025 $7.36M
Rd Expense FY 2026 · Mar 31, 2026 $2.27M
Rd Expense FY 2026 · Mar 31, 2025 $1.81M
Net Income FY 2026 · Mar 31, 2026 −$3.18M
Net Income FY 2026 · Mar 31, 2025 −$3.46M
Operating Income FY 2026 · Mar 31, 2026 −$2.46M
Operating Income FY 2026 · Mar 31, 2025 −$3.71M
Gross Profit FY 2026 · Mar 31, 2026 $7.42M
Gross Profit FY 2026 · Mar 31, 2025 $5.47M
Cost Of Revenue FY 2026 · Mar 31, 2026 $12.11M
Cost Of Revenue FY 2026 · Mar 31, 2025 $8.82M
Revenue FY 2026 · Mar 31, 2026 $19.53M
Revenue FY 2026 · Mar 31, 2025 $14.29M